Do conventional antidiabetic agents still prevail – or do incretin-based therapies demonstrate superior clinical efficacy?
Alicja Kowalska
2026-03-23
6 min. read
1 / 1
8
views
1 zdjęcie
Within Polish clinical practice, metformin hydrochloride remains the cornerstone first-line pharmacotherapy for individuals with dysregulated glucose metabolism. Nevertheless, when monotherapy fails to achieve targeted glycemic control, treatment protocols are augmented with supplementary pharmacological classes, including sulfonylurea derivatives (commonly abbreviated as PSM) and alpha-glucosidase inhibitors such as acarbose. This comprehensive evaluation will critically assess current therapeutic paradigms, juxtapose their efficacy against novel incretin-based interventions, and incorporate both metabolic outcomes and safety considerations into the comparative analysis.
Medicinal products for the treatment of diabetes
Metformin is intended for the treatment of people with type 2 diabetes mellitus, but it may be administered alone or in combination with other glucose-lowering medicinal products such as insulin or insulin. However, it is also important to note that the effectiveness of metformin depends on whether glucose metabolism is improved by reducing insulin resistance. It promotes glucose absorption in the digestive tract and improves the benefit to the glucose economy.
You have started reading a PRO article
You can preview the first chapter. To read the complete article and unlock all content, upgrade to a PRO account.
